At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 294 enrolled
Drug / intervention
Prednisolone +4 moredrug
Likely dose
Prednisolone 2.7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Withdrawal Design Trial Using Adaptive Randomization Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating Prednisolone, dipyridamole, and 3 other interventions for Rheumatoid Arthritis. Completed, enrolled 294 participants across 1 site.
Detailed Summary
Thus study will test an experimental drug called Z-102 (combination of prednisolone and dipyridamole) to treat patients with moderate to severe rheumatoid arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJun 2011
Primary CompletionAug 2012
Study CompletionSep 2012
TodayJul 2026
First PostedJun 9, 2011
Enrollment StartJun 1, 2011
Primary CompletionAug 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.1 years ago
Interventions
Prednisolonedrug
Prednisolone 2.7 mg daily
dipyridamoledrug
dipyridamole 360 mg daily
Prednisonedrug
Prednisone 5 mg daily
Z102drug
Prednisolone 2.7 mg plus dipyridamole 360 mg daily
placeboother